The capture: authorized and regulatory certainty is lower. Retatrutide was never ever to the FDA drug lack listing (as it was never ever accredited), so compounders giving it run beneath a lot more tenuous legal framing than those that taken care of semaglutide or tirzepatide in the 2023–2024 shortages. Pricing may perhaps change as enforcement e